The results of this study demonstrated markedly higher plasma PTX3 levels in the NASH patients in a comparison with the non-NASH patients, and in stages 3–4 NAFLD as compared with stages 0–2 NAFLD. The gene discussed is PTX3; the disease is metabolic dysfunction-associated steatotic liver disease.